A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label extension study. Subjects who have completed treatment in
the parent study of pertuzumab, either alone or with a combination agent, and who received at
least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if
they are continuing to receive clinical benefit.